Navigation Links
Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference
Date:12/4/2008

PLYMOUTH MEETING, Pa., Dec. 4 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that Jack Armstrong, President and CEO of Genaera, is scheduled to present at the 2008 RBC Capital Markets Healthcare Conference. The presentation is part of an RBC Capital Markets' panel discussion of obesity, entitled, "Shrinking The Obesity Epidemic," and will take place at the Westin Times Square Hotel in New York on Wednesday, December 11 at 11:00 a.m. ET.

This panel presentation is being webcast at: www.wsw.com/webcast/rbc95/panel6

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.


'/>"/>
SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genaera to Present at Therapeutic Area Partnerships 2008
2. Genaera Receives Non-Compliance Notice From NASDAQ
3. Genaera Corporations 2008 Annual Stockholder Meeting Results
4. Xmark Comments on Genaera Cost-Saving Plan
5. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
6. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
7. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
8. ATS Medical to Participate at the RBC Capital Markets Healthcare Conference
9. Individuals Associated with Vinson Hall Retirement Community, Who Survived Pearl Harbor Attack, to Participate in Navy Memorial Event December 7
10. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
11. DURECT Corporation to Participate in Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... “Crossing the ... last ten minutes of a woman’s life. “Crossing the Bar” is the creation of ... of three children. , Charlotte, who credits the inspiration of the book to ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... “Some Infallible ... of the Father. “Some Infallible Characteristics of Christ” is the creation of published author, ... of a Baptist Church for thirteen years, a preacher for over nineteen, a pastor ...
(Date:1/22/2017)... Raton, FL (PRWEB) , ... January 22, 2017 , ... ... to customers across the world, recently met with big-name retail buyers at the January ... scientific evidence of efficacy and uses the utmost safety standards in all of its ...
(Date:1/21/2017)... ... January 21, 2017 , ... Caronlab Australia, an Australian company known ... Trade Show in Hilton Head, SC, where it benefited from outstanding meetings with major ... its beauty and wellness products. At this trade show, the company had the chance ...
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at ... Oat is recognized globally as one of the healthiest cereals, XieQingkui, the founder of ... a move to sow the seed of good karma. Buddhism spirit featuring benevolence and ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23. Januar 2017  ResMed (NYSE: RMD ... 3B Medical ( Winter Haven, Florida ) ... über die Beilegung aller globalen Rechtsstreitigkeiten zwischen den Parteien ... ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren an ... 3B leisten, um das in Florida ...
(Date:1/22/2017)... , Saudi Arabia , January 22, 2017 ... US and UAE discuss ... at the World Economic Forum   "The management and ... big data and powered by artificial intelligence and this trend is going to ... ,Hospital of the Future, at the concluding day of the 47 th ...
(Date:1/21/2017)... , Jan. 20, 2017  Today, during ... Conference, "PI3K Pathways in Immunology, Growth Disorders ... (NASDAQ: INFI ) presented preclinical ... candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). Preclinical ... help overcome resistance to checkpoint inhibition by ...
Breaking Medicine Technology: